TLR7/8/9 antagonist 2_product_DataBase

Bioactivity	TLR7/8/9 antagonist 2 is an orally active TLR7/8/9 antagonist. TLR7/8/9 antagonist 2 has inhibitory activities for HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50 values of 0.011 μM, 0.029 μM and 0,052 μM, respectively.TLR7/8/9 antagonist 2 has high bioavailability in vivo.TLR7/8/9 antagonist 2 can be used for the research of auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis[1].
Target	IC50: 0.011 μM (HEK/hTLR7); 0.029 μM (HEK/hTLR8); 0.052 μM (HEK/hTLR9); 420 nM (hPBMC/TLR9).
Invitro	TLR7/8/9 antagonist 2 对 HEK/hTLR7、HEK/hTLR8 和 HEK/hTLR9 具有抑制活性，IC50 值分别为 0.011 μM、0.029 μM 和 0,052 μM[1] .TLR7/8/9 antagonist 2 对 hPBMC/TLR9 具有抑制活性，IC50 值为 420 nM[1]。
In Vivo	TLR7/8/9 antagonist 2 具有较高的体内生物利用度[1]。 Animal Model:
Name	TLR7/8/9 antagonist 2
CAS	2920729-91-3
Formula	C23H31N7
Molar Mass	405.54
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Dongdong Chen, et al. Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease. Patent WO2023046806A1.

PeptideDB